Technical Analysis for COCP - Cocrystal Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Historical COCP trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 1.91% | |
Oversold Stochastic | Weakness | 1.91% | |
Stochastic Reached Oversold | Weakness | 2.55% | |
Wide Bands | Range Expansion | 2.55% | |
Lower Bollinger Band Touch | Weakness | 2.55% | |
Oversold Stochastic | Weakness | 2.55% | |
50 DMA Resistance | Bearish | -1.82% | |
MACD Bearish Centerline Cross | Bearish | -1.82% | |
Wide Bands | Range Expansion | -1.82% | |
50 DMA Resistance | Bearish | -6.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Up 3% | about 2 hours ago | |
Up 2% | about 2 hours ago | |
Up 1% | about 2 hours ago | |
60 Minute Opening Range Breakdown | about 20 hours ago | |
Down 3% | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 09/27/2019
Cocrystal Pharma, Inc. Description
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Influenza Coronavirus Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.04 |
52 Week Low | 0.6 |
Average Volume | 3,345,731 |
200-Day Moving Average | 1.40 |
50-Day Moving Average | 1.73 |
20-Day Moving Average | 1.90 |
10-Day Moving Average | 1.80 |
Average True Range | 0.19 |
ADX | 21.95 |
+DI | 17.38 |
-DI | 26.35 |
Chandelier Exit (Long, 3 ATRs ) | 1.71 |
Chandelier Exit (Short, 3 ATRs ) | 2.08 |
Upper Bollinger Band | 2.28 |
Lower Bollinger Band | 1.51 |
Percent B (%b) | 0.09 |
BandWidth | 40.71 |
MACD Line | -0.04 |
MACD Signal Line | 0.03 |
MACD Histogram | -0.0662 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.84 | ||||
Resistance 3 (R3) | 1.85 | 1.77 | 1.79 | ||
Resistance 2 (R2) | 1.77 | 1.70 | 1.76 | 1.78 | |
Resistance 1 (R1) | 1.67 | 1.66 | 1.64 | 1.67 | 1.77 |
Pivot Point | 1.60 | 1.60 | 1.58 | 1.59 | 1.60 |
Support 1 (S1) | 1.50 | 1.53 | 1.46 | 1.49 | 1.39 |
Support 2 (S2) | 1.43 | 1.49 | 1.42 | 1.38 | |
Support 3 (S3) | 1.33 | 1.43 | 1.37 | ||
Support 4 (S4) | 1.32 |